Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary.
Center of Excellence, The Hungarian Academy of Sciences, Budapest, Hungary.
Geroscience. 2024 Apr;46(2):1561-1574. doi: 10.1007/s11357-023-00887-2. Epub 2023 Sep 1.
Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment.
在这项回顾性研究中，严重 COVID-19 患者的肺部组织自身抗体被鉴定出来。在 104 名患者中，有 53%产生了抗肺抗体，其中大多数为 IgM 类，表明它们是在感染 SARS-CoV-2 后产生的。抗肺抗体与更差的肺功能和多器官衰竭的风险相关，如果同时存在 3 种或更多自身抗体克隆（多产者），则风险更高。多产者患者比产生较少或没有自身抗体的患者年龄更大。其中一种鉴定出的自身抗体（针对一种~50 kDa 的肺蛋白）与更差的临床结果相关，包括死亡率。总之，严重的 COVID-19 与肺特异性自身抗体的产生有关，这可能会使临床结果恶化。组织蛋白质组广泛测试，如这里应用的测试，可以用于检测 COVID 后的自身免疫，以确定症状的原因，并揭示新的治疗靶点。
